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Laparoscopic Treatment of
Uterine Myomas
Elbert Tomal MD, FACOG
The treatment of leiomyomas of the uterus has traditionally been
bylaparotomy. Newer endoscopic instruments are enabling gyne
cologists to treat these common tumors with minimally invasive
surgery, resulting in same day or overnight hospitalization and
much shorter recovery times. The laparoscope is one of the
endoscopic instruments that is allowing the to occur.
Leiomyomas of the uterus are one of the most common tumors
of the uterus, estimated to occur in 20% to 25% of women of
reproductive age. A myoma is a benign smooth muscle tumor that
occurs as a discrete elliptically spheroid pseudoencapsulated mass
in and around the uterus. Various names have been given to these
tumors such as fibroids, fibromyomas, leiomyomas, myomas, and
in the Negro population that has the highest incidence, “fire balls.”
The location of the leiomyoma determines its classification. They
all start off as intramural or within the walls of the uterus. As they
enlarge most stay within the walls and remain intramural. Others
will grow towards the surface and bulge above the serosa to varying
degrees and become known as subserosal. Still others will grow
towards the endometrium and bulge into the endometrial cavity and
become known as submucosal. Subtypes of the subserous and
submucosal are called by their location - pedunculated (attached by
a stalk), intraligamentous (between the leaves of the broad liga
ment), parasitic (completely detached from the uterus), and fibroid
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polyp (on a stalk protruding thru the cervix). They can also develop
in the cervix and be known as cervical myomas These tumors vary
considerably in size from a few millimeters to 50 pounds and grow
at equally varying rates. This growth is estrogen dependent so they
are rarely found before menarche and rarely develop or enlarge
postmenopausally. Rapid growth can occur during pregnancy.1
The majority of uterine myomas are asymptomatic and are only
noted on routine pelvic examinations. The symptoms that do occur
fall into four areas. The increasing size of the tumors may cause
pelvic pressure or heaviness, abdominal enlargement, or urinary
frequency. Pain may be caused by rapid growth and degeneration or
by torsion of a pedunculated myoma. Excessively heavy bleeding is
caused by the submucus variety. Infertility may stem from blockage
of the fallopian tubes, repeated abortions from the submucus type,
endometrial changes preventing implantation, or possible biochemi
cal changes interfering with sperm transport. Sarcomatous degen
eration rarely occurs somewhere in the order of less than 0.1% of
women with leiomyomas.2
The diagnosis of uterine myomas is usually made on bimanual
pelvic examination and confirmed with pelvic ultrasound, although
CT and MRI can do the same but at higher cost. The main thing to
be ruled out is an adnexal mass, especially an ovarian carcinoma.
Once the diagnosis is definitively made the patient is educated about
leiomyomas. Then comes the question of management. There are no
known preventive measures for these tumors and no long term
medical therapies. Because the majority are asymptomatic, the
keynote to management is prudent observation with pelvic examina
tions and sometimes ultrasound between 3 and 12 months apart. If
treatment is needed, short term medical therapies are available as
well as various surgical procedures. The factors that need to be
considered in determining treatment are location and size of the
myomas, coexisting pathology, symptoms of the patient, her age and
reproductive status, and lastly her desires. A suggested workup of
the patient would include a careful ultrasound mapping of the
locations and sizes of the fibroids, doppler examination of the blood
supply, a hematocrit and hemoglobin, a biopsy of the endometrium
and possibly a bone density.3
Prior to the development of endoscopic surgery including opera
tive laparoscopy and hysteroscopy, patients with symptomatic
leiomyomas were treated by hysterectomy, usually abdominally and
sometimes vaginally. Hysterectomy is the second most common
operation in the United States. In 1985 of the 97 million women over
the age of 15 years, approximately 18.5 million had undergone a
hysterectomy. On occasion a transabdominal myomectomy was
done to relieve symptoms but preserve fertility or because the
woman desired to retain her uterus. These are major surgical proce
dures requiring postoperative stays of 3 to 6 days and 4 to 8 weeks
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total recovery time. Because of the mortality and morbidity associ
ated with major surgical procedures, any operation that will relieve
the symptoms of fibroids while avoiding major surgery deserves
consideration.2With the recent advent of operative endoscopic
surgery more options are available to both the physician and the
patient. Among the choices available now are laparoscopic assisted
vaginal hysterectomy and its various modifications, laparoscopic
myomectomy using electrosurgery, lasers or harmonic scalpels,
laparoscopic myolysis using lasers, bipolar needles with electrical
current, hyperthermia electrodes (diathermy),’° or hypothermia
probes (cyromyolysis), and hysteroscopic resection or vaporization
of submucus myomas.9The laparoscopic assisted vaginal hysterec
tomy will be discussed in another section of this issue. I only need
to mention here that it can convert an abdominal hysterectomy to a
vaginal one with a shorter hospital stay and shorter overall recovery
time. The other procedures are are done on an outpatient basis with
no hospital stay and even shorter recovery times. Three things seem
to be driving the use of these newer procedures. One is technologic
advances with a myriad ofendoscopic instruments, improved scopes
and video systems and high flow insuffiation systems Another is the
push from managed care to lower costs. Lastly there has developed
a feeling among some women to have lesser procedures done to
them than the traditional hysterectomy. Some of this comes from not
wanting to go through a long recovery period but also from not
wanting to lose part of their femininity.4
Myomectomy done through an abdominal incision has always
been considered to be a more difficult and morbid procedure than an
abdominal hysterctomy. Doing the myomectomy through a laparo
scope is even more difficult and requires much greater surgical skill.
The choice of doing an abdominal or laparoscopic myomectomy
depends on the surgeon’s skill and experience. The difficulties
involve removing the myoma from the uterus without losing much
blood, suturing the defect in the uterine wall, then removing the
myoma which may be 2 to 6cm in diameter from the abdomen where
the largest incision is a 1-2 cm. This procedure can be likened to
making an incision in the skin of an orange and removing the central
portion (the myoma). The hole that is left needs to be closed with a
series of sutures so that there is no remaing defect and the surface of
the orange is smooth again. The central portion is then morcellated
or cut into chip size pieces for removal. If this can be accomplished,
it allows the patient to be discharged on the same day of surgery and
usually back to work within a week or two.5”
Because of the technical difficulties with the myomectomy, the
technique of laparoscopic myoma coagulation or myolysis was
developed first in Germany in 1986 and started in the United States
in 1990. It involves destroying the stroma and blood supply of the
myoma using the a variety of instruments. The first to be used was
a Nd:YAG laser. This procedure succeeded in shrinking the myo
mas but with a high incidence of postoperative adhesions.’2The
second and currently the most widely used instrument is a bipolar
needle which is a 2-pronged 5 cm long needle that is attached to an
electrical generator that supplies 70 to 120 watts of continuous
power. The needle is inserted into the myoma by perforating it at 10
mm. incements accross the serosal surface, extending to the base of
the myoma forming parallel cylinders of dessicated denatured
tissue. When feasible the myoma is perforated in perpendicular
planes to destroy the stroma and its vasculature more completely. A
modification of this technique is to circumferentially perforate the
base at 5 mm. intervals to destroy the blood supply to the myoma as
much as possible while minimizing thermal damage to the serosal
surface. The coagulating effect of this procedure devascularizes the
myoma resulting in shrinkage of between 60 to 80% of the original
size. The patient is usually pretreated with a GnRH agonist such as
depo Lupron monthly for 3 to 4 months. This synthetic pituitary
hormone decreases circulating estrogens which in turn decreases the
size of the myomas preoperatively by an average of 38% and the
overall uterine size by 30% to 50%. This hormone does two things.
First it makes the laparoscopic procedure easier if shrinkage does
occur and secondly it eliminates myolysis as an option if shrinkage
does not occur. This is because long term shrinkage is less likely
after myolysis with these non responsive myomas and it virtually
rules out the rare leiomyosarcoma that is not estrogen dependent.
For women with submucus myomas the myolysis procedure can be
combined with operative hysteroscopy to remove this type of
myoma. The myoma in this case is shaved into chips or vaporized
much as in a transurethral prostate resection. Success rates with
these procedures in eliminating symptoms are reported at better than
90%. Currently myolysis shows great promise in reducing the need
for hysterectomies for myomas especially in perimenopausal women.
It appears to be a safe effective alternative to hysterectomy by
avoiding major surgery and having a shorter recovery time.”
This area of laparoscopic surgery for myomas is constantly
evolving. Other techniques of coagulation are being investigated as
well as testing which are the most effective. The use of color doppler
ultrasound to determine where the feeding vessels are located as
well as its use intraooperatively to evaluate vascular destruction
during coagulation are also being studied. There is also one inves
tigator who is exploring cryotherapy to devascularize the myomas.
As was stated earlier in this paper the push to develop alternatives
to abdominal hysterectomy for uterine myomas has opened up a
wide array of choices for both physician and patient. The future will
probably bring in not only other laparoscopic technologies but other
areas as well such as interventional radiologists obliterating the
vascular supply of the myomas or long term medical therapies for
these common tumors of women.
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